Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

In this article, we will look at where Merck & Co. Inc. (NYSE:MRK) ranks among the most undervalued quality stocks to buy according to analysts. Are More Rate Cuts Necessary to Maintain The ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

It's a companion shot to Merck's Vaxneuvance (formerly V114), which covers 15 serotypes and was approved by the FDA last year as a rival to Pfizer's Prevnar 13 and newer Prevnar 20 vaccines, which ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Merck (NYSE:MRK) announced Wednesday that a Phase 3 trial designed to test its anti-PD-1 therapy Keytruda (pembrolizumab) as part of a combination regimen in patients with a type of colorectal ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On the other hand, investors must assess some uncertainty regarding the Keytruda platform, which could lose its patent exclusivity by the end of this decade, forcing Merck to find a new growth driver.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease.